Stress kinases involved in Tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice

Neurotoxicity Research

Volumn 6, Issue 6, 2004, Pages 469-475

  Ferrer, I ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

A4 amyloid; Alzheimer disease; Amyloidplaque; APP transgenic mice; Stress kinases; Tau phosphorylation; Tauopathy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; DEGENERATIVE DISEASE; ENZYMOLOGY; GENETICS; HUMAN; IMMUNIZATION; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SENILE PLAQUE; STRESS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; SENILE PLAQUES; STRESS; TAU PROTEINS;

EID: 13944281035     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033283     Document Type: Article

References (82)

1. Anderton BH, J Betts, WP Blackstock, JP Brion, S Chapman, J Connell, R Dayanandan, JM Gallo, G Gibb, DP Hanger, M Hutton, E Kardalinou, K Leroy, S Lovestone, T Mack, CH Reynolds and M van Slegtenhorst (2001) Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 67, 73-80.
2. Atzori C, B Ghetti, R Piva, AN Srinivasan, P Zolo, MB Delisle, SS Mirra and A Migheli (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol. 60, 1190-1197.
3. Avila J, F Lim, F Moreno, C Belmonte and AC Cuello (2002) Ta u function and dysfunction in neurons, its role in neurodegenera-tive disorders. Mol. Neurobiol. 25, 213-231.
4. Behl C (1999) AD and oxidative stress, implications for novel therapeutic approaches. Progr. Neurobiol. 57, 301-323.
5. Bertram L and R Tanzi (2003) Genetics of Alzheimer's disease, In: Neurodegeneration, the Molecular Pathology of Dementia and Movement Disorders (Dickson D, Ed.) (ISN. Neuropath. Press, Basel), pp 40-46.
6. Blanchard V, S Moussaoui, C Czech, N Touchet, B Bonici, M Planche, T Canton, I Jedidi, M Gohin, O Wirths, TA Bayer, D Langui, C Duyckaerts, G Tremp and L Pradier (2003) Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice. Exp. Neurol. 184, 247-263.
7. Borchelt DR, T Ratovitsi, J van Lare, MK Lee, V Gozales, NA Jenkins, NG Copeland, DL Price and SS Sisodia (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
8. Bozyczko-Coyne D, TM O'Kane, ZL Wu, P Dobrzanski, S Murphy, JL Vaught and RW Scott (2001) CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activity, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J. Neurochem. 77, 849-863.
9. Buée-Scherrer V and M Goedert (2002) Phosphorylation of micro-tubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett. 515, 151-154.
10. Buée L, T Bussière, V Buée-Scherrer, A Delacourte and PR Hof (2000) Tau protein isoforms, phosphorylation and role in neu-rodegenerative disorders. Brain Res. Rev. 33, 95-130.
11. Daniels WM, J Hendricks, R Salie and JJ Taljaard (2001) The role of MAP-kinase superfamily in β-amyloid toxicity. Metab. Brain Dis. 16, 175-185.
12. Duyckaerts C and DW Dickson (2003) Neuropathology of Alzheimer's disease, In, Neurodegeneration, the Molecular Pathology of Dementia and Movement Disorders (Dickson D, Ed.) (ISN Neuropath. Press, Basel), pp 47-68.
13. Ferrer I, R Blanco, M Carmona and B Puig (2001a) Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/ calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tau opathies. J. Neural Transm. 108, 1397-1415.
14. Ferrer I, R Blanco, M Carmona and B Puig (2001b) Phosphorylated c-Myc expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathol. Appl. Neurobiol. 27, 343-351.
15. Ferrer I, R Blanco, M Carmona, R Ribera, E Goutan, B Puig, MJ Rey, A Cardozo, F Viñals and T Ribalta (2001c) Phosphorylated MAP kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11, 144-158.
16. Ferrer I, M Barrachina, M Tolnay, MJ Rey, N Vidal, M Carmona, R Blanco and B Puig (2003a) Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol. 13, 62-78.
17. Ferrer I, P Pastor, MJ Rey, E Muñoz, B Puig, E Pastor, R Oliva and E Tolosa (2003b) Tau phosphorylation and kinase activation in familial tau opathy linked to delN296 mutation. Neuropathol. Appl. Neurobiol. 29, 23-34.
18. Ferrer I, M Boada-Rovira, ML Sanchez-Guerra, MJ Rey and F Costa-Jussa (2004a) Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 14, 11-20.
19. Ferrer I, I Hernandez, B Puig, MJ Rey, M Ezquerra, E Tolosa and M Boada (2004b) Ubiquitin-negative mini-Pick-like bodies in the dentate gyrus in P301L tau opathy. J. Alzheimer Dis. (in press).
20. Fogarty MP, EJ Downer and V Campbell (2003) A role for c-Jun N-terminal kinase 1 (JNK-1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apop-totic cascade in cultured cortical neurons. Biochem. J. 371, 789-798.
21. Furuta A, DL Price, CA Pardo, JC Troncoso, ZS Xu, N Taniguchi and LJ Martin (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am. J. Pathol. 146, 357-362.
22. Games D, D Adams, R Alessandrini, R Barbour, P Berthelette, C Blackwell, T Carr, J Clemens, T Donaldson and F Gillespie (1995) Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. Nature 349, 704-706.
23. Ghetti B, ML Hutton and ZK Wszolek (2003) Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T), In: Neurodegeneration, The Molecular Pathology of Dementia and Movement Disorders (Dickson D, Ed.) (ISN. Neuropath. Press, Basel), pp 86-102.
24. Goedert M, M Hasegawa, R Jakes, S Lawler, A Cuenda and P Cohen (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 409, 57-62.
25. Gomez-Ramos A, J Diaz-Nido, MA Smith, G Perry and J Avila (2003) Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 71, 863-870.
26. Hartzler AW, X Zhu, SL Siedlak, RJ Castellani, J Avila, G Perry and MA Smith (2002) The p38 pathway is activated in Pick disease and progressive supranuclear palsy, a mechanistic link between mitogenic pathways, oxidative stress and tau. Neurobiol. Aging 23, 855-859.
27. Hensley K, RA Floyd, NY Zheng, R Nael, KA Robinson, X Nguyen, QN Pye, CA Stewart, J Geddes, WR Markesbery, E Patel, GV Johnson and G Bing (1999) p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72, 2053-2058.
28. Herreman A, L Serneels, W Annaert, D Collen, L Schoonjans and B De Strooper (2000) Total inactivation of? - secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell Biol. 2, 461-462.
29. Holcomb L, MN Gordon, E McGowan, X Yu, S Benkovic, P Janyzen, K Wright, I Saad, R Mueller, D Morgan, S Sanders, C Zehr, K O'Campo, J Hardy, CM Prada, C Eckman, S Younkin, K Hsiao and K Duff (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenelin 1 transgenes. Nat. Med. 4, 97-100.
30. Hsiao K, P Chapman, S Nilsen, C Exkman, Y Harigaya, S Younkin, F Yang and G Cole (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
31. Ingram EM and MG Spillantini (2002) Ta u gene mutations, dissecting the pathogenesis of FTDP-17. Trends Mol. Med. 8, 556-562.
32. Irizarry MC, M McNamara, K Fedorchak, K Hsia and BT Hyman (1997a) APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56, 965-973.
33. Irizarry MC, F Soriano, M McNamara, KJ Page, D Schenk, D Games and BT Hyman (1997b) Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 7053-7059.
34. Jang JH and YJ Surth (2002) β-amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann. NY Acad. Sci. 973, 228-236.
35. Jenkins SM, M Zinnerman, C Garner and GV Johnson (2000) Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem. J. 345 part 2, 263-270.
36. Knowles RB, J Chin, CT Ruff and BT Hyman (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibril-lary tangles, implications for MAP kinase activation in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58, 1090-1098.
37. Kruman I, AJ Bruce-Keller, D Brdeesen, G Waeg and MP Mattson (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17, 5089-5100.
38. Lee MVY, M Goedert and JQ Trojanowski (2001) Neurodegenerative tau opathies. Annu. Rev. Neurosci. 24, 1121-1159.
39. Lovestone S and CH Reynolds (1997) The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324.
40. Mark RJ, MA Lowell, WR Markesbery, K Uchida and MP Mattson (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 68, 255-264.
41. Markesberry WR and JM Carney (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol. 9, 133-146.
42. Masliah E, A Sisk, M Mallory and D Games (2001) Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J. Neuropathol. Exp. Neurol. 60, 357-368.
43. McGowan E, F Pickord and DW Dickson (2003) Alzheimer animal models, models of Aβ deposition in transgenic mice, In: Neurodegeneration, The Molecular Pathology of Dementia and Movement Disorders (Dickson D, Ed.) (ISN. Neuropath. Press, Basel), pp 74-79.
44. Morishima Y, Y Gotoh, J Zieg, T Barrett, H Takano, R Flavell, RJ Davis, Y Shirasaki and ME Greenberg (2001) β-amyloid induces neuronal apopotosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551-7560.
45. Nicoll JAR, D Wilkinson, C Holmes, O Steart, H Markham and RO Weller (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide, a case report. Nat. Med. 9, 4448-4452.
46. Nunomura A, G Perry, MA Papolla, R Wade, K Hirai, S Ciba and MA Smith (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964.
47. Nunomura A, G Perry, G Aliev, K Hiari, A Takeda, EK Balraj, PK Jones, H Ghanbari, T Wataya, S Shimohama, S Chiba, CS Atwood, RB Petersen and MA Smith (2001) Oxidative damage is the earliest event in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 60, 759-767.
48. Obaya AJ, MK Mateyak and JM Sedivy (1999) Mysterious liaisons, the relationship between c-Myc and the cell cycle. Oncogene 18, 2934-2941.
49. Odetti P, S Garibaldi, R Norese, G Angelini, L Marinelli, S Valentini, S Menini, N Traverso, D Zaccheo, S Siedlak, G Perry, MA Smith and M Tabaton (2000) Lipoperxidation is selectively involved in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 59, 393-397.
50. Pappolla MA, RA Omar, KS Kim and NK Robakis (1992) Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am. J. Pathol. 140, 621-628.
51. Pappolla MA, YJ Chyan, RA Omar, K Hsiao, G Perry, MA Smith and P Bozner (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease, a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152, 871-877.
52. Pei JJ, E Braak, H Braak, K Grundque-Iqbal, W Winblad and RF Cowburn (2001) Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimer's Dis. 3, 41-48.
53. Perry G, RJ Castellani, K Hirai and MA Smith (1998) Reactive oxygen species mediate cellular damage in Alzheimer's disease. J. Alzheimer Dis. 1, 45-55.
54. Perry G, H Roder, A Nunomura, A Takeda, AL Friedlich, X Zhu, AL Raina, N Holbrook, SL Siedlak, PLR Harris and MA Smith (1999) Activation of extracellular receptor kinase (ERK) in Alzheimer's disease links oxidative stress to abnormal tau phos-phorylation. NeuroReport 10, 2411-2415.
55. Puig B, T Gómez-Isla, E Ribe, M Cuadrado and I Ferrer (2004a) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/ JNK-P) and p38 kinase (p38-P) links oxidative stress and tau hyperphosphorylation in neurites surrounding Aβ plaques in APP Tg2576 mice. Neuropathol. Appl. Neurobiol. (in press).
56. Puig B, F Viñals and I Ferrer (2004b) Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol. (in press).
57. Reynolds CH, AR Nebreda, GM Gibb, MA Utton and BH Anderton (1997a) Reactivating kinase/p38 phosphorylates tau protein in vitro. J. Neurochem. 69, 191-198.
58. Reynolds CH, MA Utton, GM Gibb, A Yates and BH Anderton (1997b) Stress-activated protein kinase/c-Jun N -terminal kinase phosphorylates tau protein. J. Neurochem. 68, 1736-1744.
59. Reynolds CH, JC Betts, WP Blackstock, AR Nebreda and BH Anderton (2000) Phosphorylation sites on tau identified by nano-electrospray mass spectrometry, differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N -terminal kinase and p38, and glycogen synthase kinase-3β. J. Neurochem. 74, 1587-1595.
60. Savage MJ, YG Lin, JR Ciallella, DG Flood and RW Scott (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385.
61. Selznick LA, DM Holtnman, BH Han, M Gökden, AN Srinavasan, EM Jonson and KA Roth (1999) In situ immunodetection of neu-ronal caspase-3 activation in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58, 1020-1026.
62. Smith MA, LM Sayre, MP Vitek, VM Monnier and G Perry (1995) Early AGE in Alzheimer's disease. Nature 374, 316.
63. Smith MA, K Hirai, K Hsiao, MA Pappolla, PL Harris, SL Siedlak, M Tabaton and G Perry (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212-2215.
64. Smith MA, CA Rottkamp, A Nunomura, AK Raina and G Perry (2000) Oxidative stress in Alzheimer's disease. Biochem. Biophys. Acta 1502, 139-144.
65. Spillantini MG and M Goedert (1998) Ta u protein pathology in neurodegenerative diseases. Trends Neurosci. 21, 428-433.
66. Sturchler-Pierrat C, D Abramowski, M Duke, KH Wiederhold, C Mistl, S Rothacher, B Ledermann, K Burki, P Frey, PA Paganetti, C Waridel, ME Calhoun, M Jucker, A Probst, M Staufenbiel and B Sommer (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287-13292.
67. Sun A, M Liu, XV Nguyen and G Bing (2003) p38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp. Neurol. 183, 394-405.
68. 2 and 4-hydroxynonenal mediate β-amyloid-induced neuronal apoptosis by activating JNKs and p38 MAPKs. Exp. Neurol. 180, 144-155.
69. Togo T, N Sahara, SH Yen, N Cookson, T Ishizawa, M Hutton, R De Silva, A Lees and DW Dickson (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547-556.
70. Tomidokoro Y, Y Harigaya, E Matsubara, M Ikeda, T Kawarabayashi, T Shirao, K Ishiguro, K Okamoto, SG Younkin and M Shoji (2001) Brain Aβ amyloidosis in APP(Sw) mice induces accumulation of presenilin-1 and tau. J. Pathol. 194, 500-506.
71. Troy CM, SA Rabacchi, Z Xu, AC Maroney, TJ Connors, ML Shelanski and LA Greene (2001) Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J. Neurochem. 77, 157-164.
72. Wei W, DD Norton, X Wang and JW Kusiak (2002a) Aβ 17-42 in Alzheimer's diseae actiavers JNK and caspase-8 leading to neu-ronal apoptosis. Brain 125, 2036-2043.
73. Wei W, X Wang and JW Kusiak (2002b) Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 277, 17649-17656.
74. Zhang Z, P Nadeau, W Song, D Donoviel, M Yuan, A Bernstein and BA Yankner (2000) Presenilins are required for? - secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat. Cell Biol. 2, 463-465.
75. Zhu X, CA Rottkamp, H Boux, A Takeda, G Perry and MA Smith (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59, 880-888.
76. Zhu X, RJ Castellani, A Takeda, A Nunomura, CS Atwood, G Perry and MA Smith (2001a) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer's disease, the two hit hypothesis. Mech. Ageing Dev. 123, 39-46.
77. Zhu X, AK Raina, CA Rottkamp, G Aliev, G Perry, H Boux and MA Smith (2001b) Activation and redistribution of c-Jun N-ter-minal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76, 435-441.
78. Zhu X, CA Rottkamp, A Hartzler, Z Sun, A Takeda, H Boux, S Shimohama, G Perry and MA Smith (2001c) Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. 79, 311-318.
79. Zhu X, HG Lee, AK Raina, G Perry and MA Smith (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11, 270-281.
80. Zhu X, O Ogawa, Y Wang, G Perry and MA Smith (2003a) JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J. Neurochem. 85, 87-93.
81. Zhu X, AK Raina, HG Lee, M Chao, A Nunomura, M Tabaton, RB Petersen, G Perry and MA Smith (2003b) Oxidative stress and neuronal adaptation in Alzheimer disease, the role of SAPK pathways. Antioxid. Redox Signal 5, 571-576.
82. Zhu X, Z Sun, HG Lee, SL Siedlak, G Perry and MA Smith (2003c) Distribution, levels, and activation of MEK1 in Alzheimer's disease. J. Neurochem. 86, 136-142.